Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...

Women with BRCA1 or BRCA2 mutations have a very high lifetime risk of developing breast and ovarian cancer. Women have options to reduce their risk of cancer. Options to reduce breast cancer risk ...

Researchers determined the clinical classification of more than 90% of potential BRCA2 variants of uncertain significance in ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying ...

AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...

Followed categories will be added to My News. She has one of the most commonly inherited gene mutations – BRCA2 – which increases the risk of breast, ovarian and prostate cancers. Mia tested ...

"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words eight years ago from the mother of a child with Fanconi anemia (FA).

A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk patients ...